The different roles of the adaptive immune system in cancer are beginning to unfold. The dramatic responses to immune check point drugs in some tumors generated an accelerated need for understanding the complex set of interactions between tumor and immune cells. In view of the major pathophysiological role of immune cells in hepatocellular carcinoma, it is not surprising that malignant hepatocytes interact extensively with adaptive immune cells, resulting in both protumor immunopathology and antitumor protective immunity. Identifying potential responders to drugs that target the adaptive immune system, monitoring their immune response to the tumor, and devising the best treatment combinations depends on understanding the complex set of interactions taking place within the tumor and in the adjacent hepatic parenchyma.
Bibliographical noteFunding Information:
Research in M.H.’s laboratory is supported by an ERC consolidator grant (Hepatometabopath), This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667273 and an SFB/TR 209 (LIVER CANCER).
Research in E.P.’s laboratory is supported by grants from the Dr. Miriam and Sheldon G. Adelson Medical Research foundation (AMRF), the European Research Council (ERC-StG livermicroenv), the Israel Science Foundation Center of Excellence Grant 2084/5, and the DKFZ-MOST collaboration in cancer research.
© 2017 by Thieme Medical Publishers, Inc.
- chronic inflammation
- hepatocellular carcinoma
- immune checkpoint
- mouse models